Influence of method of systemic administration of adenovirus on virus-mediated toxicity: Focus on mortality, virus distribution, and drug metabolism

Journal of Pharmacological and Toxicological Methods

Volumn 58, Issue 3, 2008, Pages 222-232

  Boquet, Michael P ^a   Wonganan, Piyanuch ^a   Dekker, Joseph D ^a   Croyle, Maria A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adenovirus; Drug metabolism; Liver; Route of administration; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; CYTOCHROME P450; CYTOCHROME P450 2C11; CYTOCHROME P450 3A4;

ADENOVIRUS; ADENOVIRUS 5; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; JUGULAR VEIN; LIVER; MALE; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; RAT; SPLEEN; TOXICITY TESTING; TRANSGENE; VIRUS GENOME; VIRUS PARTICLE;

ADENOVIRIDAE; ALANINE TRANSAMINASE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ASPARTATE AMINOTRANSFERASES; BETA-GALACTOSIDASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENOME, VIRAL; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; LUNG; MALE; MEMBRANE PROTEINS; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; STEROID 16-ALPHA-HYDROXYLASE; TIME FACTORS; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; RATTUS;

EID: 55249102364     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.07.003     Document Type: Article

References (53)

1. Altaras N.E., Aunins J.G., Evans R.K., Kamen A., Konz J.O., and Wolf J.J. Production and formulation of adenovirus vectors. Advances in Biochemical Engineering, Biotechnology 99 (2005) 193-260
2. Baker A.H., Mcvey J.H., Waddington S.N., Di Paolo N.C., and Shayakhmetov D.M. The influence of blood on in vivo adenovirus bio-distribution and transduction. Molecular Theraphy 15 (2007) 1410-1416
3. Ben-Gary H., McKinney R.L., Rosengart T., Lesser M.L., and Crystal R.G. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Molecular Therapy 6 (2002) 287-297
4. Bessis N., GarciaCozar F.J., and Boissier M.C. Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Theraphy 11 (2004) S10-S17
5. Brange J., Andersen L., Laursen E.D., Meyn G., and Rasmussen E. Toward understanding insulin fibrillation. Journal of Pharmaceutical Sciences 86 (1997) 517-525
6. Callahan S.M., Boquet M.P., Ming X., Brunner L.J., and Croyle M.A. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. Journal of Gene Medicine 8 (2006) 566-576
7. Callahan S.M., Ming X., Lu S.K., Brunner L.J., and Croyle M.A. Considerations for use of recombinant adenoviral vectors: Dose effect on hepatic cytochromes P450. Journal of Pharmacology and Experimental Therapeutics 312 (2005) 492-501
8. Callahan, S.M., Wonganan, P., and Croyle, M.A. (in review). Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. European Journal of Pharmaceutics and Biopharmaceutics.
9. Campos S.K., and Barry M.A. Current advances and future challenges in adenoviral vector biology and targeting. Current Gene Theraphy 7 (2007) 189-204
10. Cattaneo R., Miest T., Shashkova E.V., and Barry M.A. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nature Reviews. Microbiology 6 (2008) 529-540
11. Cheng K., and Schenkman J. Testosterone metabolism by cytochrome P-450 isozymes RLM3 and RLM5 and by microsomes. Metabolite identification. Journal of Biological Chemistry 258 (1983) 11738-11744
12. Cocchetto D.M., and Bjornsson T.D. Methods for vascular access and collection of body fluids from the laboratory rat. Journal of Pharmaceutical Sciences 72 (1983) 465-492
13. Croyle M.A., Chirmule N., Zhang Y., and Wilson J.M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Human Gene Theraphy 13 (2002) 1887-1900
14. Demers G.W., Johnson D.E., Tsai V., Wen S.F., Quijano E., Machemer T., et al. Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. Cancer Research 63 (2003) 4003-4008
15. Galdiero F. Adenovirus aggregation and preservation in extracellular environment. Archives Virology 59 (1979) 99-105
16. Garcia-Banuelos J., Siller-Lopez F., Miranda A., Aguilar L.K., Aguilar-Cordova E., and Armendariz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Theraphy 9 (2002) 127-134
17. Gooch III W.M., and Mogabgab W.J. Simultaneous oral administration of live adenovirus types 4 and 7 vaccines. Protection and lack of emergence of other types. Archives of Environmental Health 25 (1972) 388-394
18. Graham F.L., and van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52 (1973) 456-467
19. Gutsmann T., Schromm A.B., and Brandenburg K. The physicochemistry of endotoxins in relation to bioactivity. International Journal of Medical Microbiology 297 (2007) 341-352
20. Harrison L.I., and Gibaldi M. Physiologically based pharmacokinetic model for digoxin distribution and elimination in the rat. Journal of Pharmaceutical Sciences 66 (1977) 1138-1142
21. Hartman Z.C., Appledorn D.M., and Amalfitano A. Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Research 132 (2008) 1-14
22. Hui Y.H., Huang N.H., Ebbert L., Bina H., Chiang A., Maples C., et al. Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. Journal of Pharmacological and Toxicological Methods 56 (2007) 256-264
23. Johannessen W., Tyssebotn T., and Aarbakke J. Antipyrine and acetaminophen kinetics in the rat: Comparison of data on blood samples from the cut tail and a cannulated femoral artery. Journal of Pharmaceutical Sciences 71 (1982) 1352-1356
24. Kreppel F., and Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide. Molecular Theraphy 16 (2008) 16-29
25. Le H.T., Boquet M.P., Clark E.A., Callahan S.M., and Croyle M.A. Renal pathophysiology after systemic administration of recombinant adenovirus: Changes in renal cytochromes P450 based on vector dose. Human Gene Theraphy 17 (2006) 1095-1111
26. Li Z., and Blatteis C.M. Fever onset is linked to the appearance of lipopolysaccharide in the liver. Journal of Endotoxin Research 10 (2004) 39-53
27. Ling S., and Jamali F. Effect of cannulation surgery and restraint stress on the plasma corticosterone concentration in the rat: Application of an improved corticosterone HPLC assay. Journal of Pharmacy and Pharmaceutical Sciences 6 (2003) 246-251
28. Maizel Jr. J.V., White D.O., and Scharff M.D. The polypeptides of adenovirus I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36 (1968) 115-125
29. Morgan E.T., Goralski K.B., Piquette-Miller M., Renton K.W., Robertson G.R., Chaluvadi M.R., et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition 36 (2008) 205-216
30. Morrissey R.E., Horvath C., Snyder E.A., Patrick J., and MacDonald J.S. Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicological Sciences 65 (2002) 266-275
31. Murakami P., Pungor E., Files J., Do L., van Rijnsoever R., Vogels R., et al. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing helper dependent E1 positive particles. Human Gene Theraphy 13 (2002) 909-920
32. Ozer J., Ratner M., Shaw M., Bailey W., and Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 245 (2008) 194-205
33. Pace C.N. Conformational stability of globular proteins. Trends in Biochemical Sciences 15 (1990) 14-17
34. Rand R.P., Burton A.C., and Ing T. The tail of the rat: In temperature, regulation and acclimatization. Canadian Journal of Physiology and Pharmacology 43 (1965) 257-267
35. Romanovsky A.A., Kulchitsky V.A., Simons C.T., and Sugimoto N. Methodology of fever research: Why are polyphasic fevers often thought to be biphasic?. The American Journal of Physiology 275 (1998) R332-R338
36. Rudaya A.Y., Steiner A.A., Robbins J.R., Dragic A.S., and Romanovsky A.A. Thermoregulatory responses to lipopolysaccharide in the mouse: Dependence on the dose and ambient temperature. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 289 (2005) R1244-R1252
37. Sakurai H., Kawabata K., Sakurai F., Nakagawa S., and Mizuguchi H. Innate immune response induced by gene delivery vectors. International Journal of Pharmaceutics 354 (2008) 9-15
38. Seiler M.P., Cerullo V., and Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: Challenges and prospects. Current Gene Theraphy 7 (2007) 297-305
39. Shaw A.A., Hall S.D., Franklin M.R., and Galinsky R.E. The influence of l-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metabolism and Disposition 30 (2002) 177-182
40. Smith C.N., Neptun D.A., and Irons R.D. Effect of sampling site and collection method on variations in baseline clinical pathology parameters in Fischer-344 rats. II. Clinical hematology. Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology 7 (1986) 658-663
41. Smith J.S., Tian J., Lozier J.N., and Byrnes A.P. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Molecular Theraphy 9 (2004) 932-941
42. Smith J.S., Tian J., Muller J., and Byrnes A.P. Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Theraphy 11 (2004) 431-438
43. Smith J.S., Xu Z., Tian J., Stevenson S.C., and Byrnes A.P. Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Human Gene Theraphy 19 (2008) 547-554
44. Terao N., and Shen D.D. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. Journal of Pharmacology and Experimental Therapeutics 227 (1983) 369-375
45. Thornton C.A., and Ballow M. Safety of intravenous immunoglobulin. Archives of Neurology 50 (1993) 135-136
46. Thrivikraman K.V., Huot R.L., and Plotsky P.M. Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Research. Brain Research Protocols 10 (2002) 84-94
47. Top Jr. F.H. Control of adenovirus acute respiratory disease in U.S. Army trainees. Yale Journal of Biology and Medicine 48 (1975) 185-195
48. Tse F., Chang T., Finkelstein B., Ballard F., and Jaffe J.M. Influence of mode of intravenous administration and blood sample collection on rat pharmacokinetic data. Journal of Pharmaceutical Sciences 73 (1984) 1599-1601
49. Vähä-Koskela M.J., Heikkilä J.E., and Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Letter 254 (2007) 178-216
50. Waxman D., Ko A., and Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. Journal of Biological Chemistry 258 (1983) 11937-11947
51. Wu H., and Curiel D.T. Fiber-modified adenoviruses for targeted gene therapy. Methods in Molecular Biology 434 (2008) 113-132
52. Yang Z.R., Wang H.F., Zhao J., Peng Y.Y., Wang J., Guinn B.A., et al. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Theraphy 14 (2007) 599-615
53. Zaldumbide A., and Hoeben R.C. How not to be seen: Immune-evasion strategies in gene therapy. Gene Therapy 15 (2008) 239-246